Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

Comment: Immunotherapy plus chemotherapy in bladder cancer

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer

Comment: Keynote 522 trial

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma

Ovarian highlights from ESMO 2019

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin

Comment: Immunotherapy combination for advanced NSCLC

More ovarian cancer patients benefit from maintenance combined targeted therapy

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer